560 related articles for article (PubMed ID: 23775260)
21. Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial.
Dachs TM; Duca F; Rettl R; Binder-Rodriguez C; Dalos D; Ligios LC; Kammerlander A; Grünig E; Pretsch I; Steringer-Mascherbauer R; Ablasser K; Wargenau M; Mascherbauer J; Lang IM; Hengstenberg C; Badr-Eslam R; Kastner J; Bonderman D
Eur Heart J; 2022 Sep; 43(36):3402-3413. PubMed ID: 35909264
[TBL] [Abstract][Full Text] [Related]
22. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial.
Hoeper MM; Halank M; Wilkens H; Günther A; Weimann G; Gebert I; Leuchte HH; Behr J
Eur Respir J; 2013 Apr; 41(4):853-60. PubMed ID: 22936711
[TBL] [Abstract][Full Text] [Related]
23. Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study).
Marra AM; Halank M; Benjamin N; Bossone E; Cittadini A; Eichstaedt CA; Egenlauf B; Harutyunova S; Fischer C; Gall H; Ghofrani HA; Hoeper MM; Lange TJ; Olsson KM; Klose H; Grünig E
Respir Res; 2018 Dec; 19(1):258. PubMed ID: 30567595
[TBL] [Abstract][Full Text] [Related]
24. Soluble guanylate cyclase stimulators in pulmonary hypertension.
Stasch JP; Evgenov OV
Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
[TBL] [Abstract][Full Text] [Related]
25. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2).
Simonneau G; D'Armini AM; Ghofrani HA; Grimminger F; Hoeper MM; Jansa P; Kim NH; Wang C; Wilkins MR; Fritsch A; Davie N; Colorado P; Mayer E
Eur Respir J; 2015 May; 45(5):1293-302. PubMed ID: 25395036
[TBL] [Abstract][Full Text] [Related]
26. Riociguat for Sarcoidosis-Associated Pulmonary Hypertension: Results of a 1-Year Double-Blind, Placebo-Controlled Trial.
Baughman RP; Shlobin OA; Gupta R; Engel PJ; Stewart JI; Lower EE; Rahaghi FF; Zeigler J; Nathan SD
Chest; 2022 Feb; 161(2):448-457. PubMed ID: 34363816
[TBL] [Abstract][Full Text] [Related]
27. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.
Mitrovic V; Seferovic P; Dodic S; Krotin M; Neskovic A; Dickstein K; de Voogd H; Böcker C; Ziegler D; Godes M; Nakov R; Essers H; Verboom C; Hocher B
Circ Heart Fail; 2009 Nov; 2(6):523-31. PubMed ID: 19919976
[TBL] [Abstract][Full Text] [Related]
28. [SPECIFICS OF INHALED ILOPROST PHARMACODYNAMICS IN PATIENTS WITH SEVERE LEFT VENTRICULAR SYSTOLIC DYSFUNCTION].
Bautin AE; Iakovlev AS; Tashkhanov DM; Datsenko SV; Marichev AO; Popov MA; Fedotov PA
Anesteziol Reanimatol; 2015; 60(2):4-7. PubMed ID: 26148353
[TBL] [Abstract][Full Text] [Related]
29. A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers.
Nagaraja V; Spino C; Bush E; Tsou PS; Domsic RT; Lafyatis R; Frech T; Gordon JK; Steen VD; Khanna D
Arthritis Res Ther; 2019 Sep; 21(1):202. PubMed ID: 31481106
[TBL] [Abstract][Full Text] [Related]
30. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy.
Ghofrani HA; Grimminger F
Eur Respir Rev; 2009 Mar; 18(111):35-41. PubMed ID: 20956121
[TBL] [Abstract][Full Text] [Related]
31. Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension.
Kim NH; D'Armini AM; Grimminger F; Grünig E; Hoeper MM; Jansa P; Mayer E; Neurohr C; Simonneau G; Torbicki A; Wang C; Fritsch A; Davie N; Ghofrani HA
Heart; 2017 Apr; 103(8):599-606. PubMed ID: 28011757
[TBL] [Abstract][Full Text] [Related]
32. The safety and effectiveness of riociguat to treat chronic thromboembolic pulmonary hypertension.
DeSouza SA; Preston IR
Expert Rev Cardiovasc Ther; 2015 May; 13(5):467-76. PubMed ID: 25797801
[TBL] [Abstract][Full Text] [Related]
33. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models.
Sharkovska Y; Kalk P; Lawrenz B; Godes M; Hoffmann LS; Wellkisch K; Geschka S; Relle K; Hocher B; Stasch JP
J Hypertens; 2010 Aug; 28(8):1666-75. PubMed ID: 20613628
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
Germino FW
Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
[TBL] [Abstract][Full Text] [Related]
35. Animal models related to congenital heart disease and clinical research in pulmonary hypertension.
Loukanov T; Geiger R; Agrawal R
Cardiology; 2010; 116(1):18-25. PubMed ID: 20424448
[TBL] [Abstract][Full Text] [Related]
36. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.
Lewis GD; Shah R; Shahzad K; Camuso JM; Pappagianopoulos PP; Hung J; Tawakol A; Gerszten RE; Systrom DM; Bloch KD; Semigran MJ
Circulation; 2007 Oct; 116(14):1555-62. PubMed ID: 17785618
[TBL] [Abstract][Full Text] [Related]
37. Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
Belik J
Curr Opin Investig Drugs; 2009 Sep; 10(9):971-9. PubMed ID: 19705340
[TBL] [Abstract][Full Text] [Related]
38. Treatment of pulmonary hypertension caused by left heart failure with pulmonary arterial hypertension-specific therapies: lessons from the right and LEPHT.
Rubin LJ
Circulation; 2013 Jul; 128(5):475-6. PubMed ID: 23775259
[No Abstract] [Full Text] [Related]
39. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ;
J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129
[TBL] [Abstract][Full Text] [Related]
40. Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension.
Givertz MM; Hare JM; Loh E; Gauthier DF; Colucci WS
J Am Coll Cardiol; 1996 Dec; 28(7):1775-80. PubMed ID: 8962566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
